Sort by
Keyphrases
Multicenter Cohort Study
100%
Critically Ill Patients
100%
COVID-19
100%
Tocilizumab
100%
Intensive Care Unit
33%
Pneumonia
16%
Hazard Ratio
16%
Electronic Medical Records
16%
Multivariable
16%
Adult Patients
16%
Comorbidity
16%
Immunosuppressive Therapy
16%
Survival Analysis
16%
Lung Injury
16%
Inflammatory Markers
16%
Case Fatality Rate
16%
Critical Illness
16%
Medical Record Review
16%
Secondary Infection
16%
Dysregulated Immune Response
16%
Alanine Aminotransferase Level
16%
Support Measures
16%
Creatinine Level
16%
Multicenter Retrospective Cohort Study
16%
Procalcitonin
16%
Medicine and Dentistry
Cohort Analysis
100%
Tocilizumab
100%
Coronavirinae
100%
Diseases
100%
Intensive Care Unit
33%
Electronic Patient Record
16%
Prevalence
16%
Hazard Ratio
16%
Immune Response
16%
Retrospective Cohort Study
16%
Creatinine
16%
Critical Illness
16%
Alanine Aminotransferase
16%
Survival Analysis
16%
Case Fatality Rate
16%
Secondary Infection
16%
Procalcitonin
16%
Comorbidity
16%
Primary Outcome
16%
Pharmacology, Toxicology and Pharmaceutical Science
Cohort Study
100%
Tocilizumab
100%
Coronavirinae
100%
Diseases
100%
Prevalence
16%
Creatinine
16%
Alanine Aminotransferase
16%
Case Fatality Rate
16%
Critical Illness
16%
Secondary Infection
16%
Procalcitonin
16%
Comorbidity
16%
Immunology and Microbiology
Coronavirinae
100%
Tocilizumab
100%
Prevalence
16%
Immune Response
16%
Case Fatality Rate
16%
Electronic Medical Record
16%
Alanine Aminotransferase Level
16%
Procalcitonin
16%
Comorbidity
16%
Infection
16%